Drugs / Anselamimab
Anselamimab
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT07615270 | Jul 2026 → Jul 2028 expected | AL amyloidosis | Stanford University | Not yet recruiting | No outcome recorded |
| Phase 12 trials | ||||||
| Phase 1 | NCT02245867 | Oct 2014 → Jul 2017 | AL amyloidosis | Alexion Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01815086 | Dec 2008 → Jul 2013 | AL amyloidosis | University of Tennessee | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04304144 | Mar 2020 → Nov 2023 | AL amyloidosis | Alexion Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 32 trials · 2 missed | ||||||
| Phase 3 | NCT04512235 | Nov 2020 → Apr 2025 overdue | AL amyloidosis | Alexion Pharmaceuticals, Inc. | Active not recruiting | Missed primary |
| Phase 3 | NCT04504825 | Aug 2020 → May 2025 overdue | AL amyloidosis | Alexion Pharmaceuticals, Inc. | Active not recruiting | Missed primary |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2026-05-29 | AstraZeneca | Results CARES Phase III clinical programme did not meet primary endpoint in overall light chain amyloidosis population, however, demonstrated anselamimab as potential first anti-fibril therapy in kappa light chain amyloidosis astrazeneca.com ↗
Anselamimab demonstrated 62% improvement in survival and 71% reduction in cardiovascular hospitalisations in prespecified kappa light-chain amyloidosis subgroup |
| 2025-07-16 | AstraZeneca | Results Update on CARES Phase III clinical programme of anselamimab in light chain amyloidosis astrazeneca.com ↗
Anselamimab showed highly clinically meaningful improvement in time to ACM and frequency of CVH in a prespecified subgroup of patients, compared to placebo. |
| 2023-11-29 | AstraZeneca | Results AstraZeneca advances scientific leadership in haematology at ASH 2023 astrazeneca.com ↗
24-month results of a Phase II trial will demonstrate the safety and tolerability of CAEL-101 in combination with cyclophosphamide-bortezomib-dexamethasone with or without daratumumab for the treatment of AL amyloidosis. |
All press releases naming this drug 3 releases
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Anselamimab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07615270 ↗ |
| Known as | 11-1F4 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02245867 ↗ |
| Known as | CAEL-101 | “A Pilot Study of CAEL-101/Anselamimab in Patients With AL Amyloidoma and Measurable Tissue Involvement” NCT07615270 ↗ |
| Known as | Mu 11-F4 | “Radioimmunoimaging (PET/CT) of Patients With AL Amyloidosis Using the 124I-Labeled Amyloid-Reactive Monoclonal Antibody (mAb) Murine (Mu) 11-F4” NCT01815086 ↗ |
| Modality | Monoclonal antibody | “radiolabeled amyloid-reactive monoclonal antibody (mAb)” NCT01815086 ↗ |
| Route | Intravenous | “intravenous infusion” NCT01815086 ↗ |